Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $12.50.

AMRX has been the subject of several recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st.

Amneal Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ AMRX opened at $12.59 on Friday. The stock has a fifty day moving average price of $10.81 and a 200 day moving average price of $9.26. Amneal Pharmaceuticals has a 12-month low of $6.68 and a 12-month high of $12.68. The company has a market cap of $3.96 billion, a P/E ratio of 1,259.86 and a beta of 1.21.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, October 30th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%.The company had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $11.72, for a total transaction of $586,000.00. Following the sale, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the transaction, the executive vice president directly owned 146,403 shares of the company’s stock, valued at $1,745,123.76. This represents a 47.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 231,856 shares of company stock worth $2,743,724. Corporate insiders own 26.56% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AMRX. Allianz Asset Management GmbH acquired a new stake in Amneal Pharmaceuticals in the first quarter valued at $326,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Amneal Pharmaceuticals in the 1st quarter worth about $374,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Amneal Pharmaceuticals by 30.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 57,276 shares of the company’s stock valued at $480,000 after purchasing an additional 13,464 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of Amneal Pharmaceuticals by 1,281.5% during the first quarter. Mackenzie Financial Corp now owns 168,830 shares of the company’s stock worth $1,415,000 after purchasing an additional 156,609 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in Amneal Pharmaceuticals by 110.7% in the first quarter. XTX Topco Ltd now owns 82,276 shares of the company’s stock worth $689,000 after purchasing an additional 43,221 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.